Off-label prescribing refers to prescribing a Therapeutic Goods
Administration (TGA)–approved medicine for an indication, dose, route of
administration or patient group that is not listed in the approved product information.
It also includes modification of the dosage form outside of the
preparation directions provided in the product information (e.g. crushing or dividing tablets that are not intended to be
crushed or divided, or using the medicine for extemporaneous compounding).1
Off-label prescribing is a common and sometimes necessary
practice. Prescribers (medical and non-medical) need to be aware of the clinical,
safety, ethical and legal issues associated with off-label prescribing.2,3
The Council of Australian Therapeutic
Advisory Groups (CATAG) has updated its guidance for the off-label use of medicines, supported
by funding from the Australian Commission on Safety and Quality in Heath Care.1
A key change is that the scope has been expanded to include
primary care in addition to hospitals.
There are 8 guiding principles that provide a practical
framework for decision-making about off-label prescribing based on the strength
of available evidence, clinical circumstances and patient preference.1 The
principles emphasise:
- using a medicine off label only when other options are unavailable, less
suitable, ineffective or not tolerated
- using the highest quality and most clinically relevant evidence
available to guide prescribing decisions
- seeking expert advice when considering off-label use that is outside
routine or standard care
- consumer involvement through shared decision-making with informed
consent, especially for non-routine use of a medicine or where evidence is
limited
- appropriate documentation and monitoring of off-label medicine use
- communication of off-label use at transitions of care
- evaluation of outcomes and, where appropriate, dissemination of
findings to add to the evidence base
- consideration of legal and professional responsibilities.
The Australian Health Practitioner Regulation
Agency (AHPRA) has also recently published a brief guidance
for off-label prescribing (and prescribing of unapproved medicines).3 The AHPRA guidance emphasises that
prescribers should ensure they have the necessary knowledge, skills and
training to provide safe care when prescribing off-label or unapproved
medicines, and comply with relevant jurisdictional and national legislative and
regulatory requirements. It notes that the National Prescribing Competencies
Framework includes a competency on off-label prescribing that covers:3
- establishing therapeutic need
- shared decision-making and informed consent
- documenting the reason for use in the patient’s health record.
The AHPRA guidance also discusses managing conflicts
of interest, ensuring continuity of care and reporting adverse drug reactions
to the TGA.3
The CATAG has produced a consumer
counselling tool that supports healthcare professionals when discussing
off-label use of a medicine with patients and carers and facilitates shared
decision-making and informed consent.4 While the consumer tool has been
designed for hospitals, it may be useful in other settings.
Together these guides and tools can help
clinicians to optimise quality and safety of patient care when prescribing
off-label medications.
Australian Prescriber welcomes Feedback.